Pyxis Oncology, Inc. Profile Avatar - Palmy Investing

Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targ…

Biotechnology
US, Cambridge [HQ]

Cash Flow Statements

Loading...
End of PYXS's Analysis
CIK: 1782223 CUSIP: 747324101 ISIN: US7473241013 LEI: - UEI: -
Secondary Listings
PYXS has no secondary listings inside our databases.